Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals has continued to execute its $250 million share buyback programme, repurchasing 299,445 ordinary shares on 5 March 2026 via Citigroup Global Markets at a volume‑weighted average price of 1,230.08 pence. The company plans to cancel these shares, and has now bought 1,327,164 shares at a cost of £16.9 million, reducing free float to 220,559,289 voting shares and signalling ongoing capital returns and balance sheet confidence to investors.
Following the latest transactions, Hikma holds 12,833,233 shares in treasury while maintaining 220,559,289 ordinary shares in issue, which defines the current voting rights base. The continued buyback activity underscores management’s commitment to returning excess capital to shareholders, potentially supporting earnings per share and reinforcing the company’s valuation in the pharmaceuticals sector.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is an international pharmaceuticals company listed in London and on Nasdaq Dubai. It manufactures and markets generic and branded medicines, with a focus on injectable and oral treatments for global healthcare markets.
Average Trading Volume: 1,081,084
Technical Sentiment Signal: Sell
Current Market Cap: £2.74B
See more insights into HIK stock on TipRanks’ Stock Analysis page.